High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: A phase II study

Clinical Oncology

Volumn 17, Issue 8, 2005, Pages 630-635

  Stemmler, H Joachim ^a   Kahlert, S ^a   Brudler, O ^b   Beha, M ^b   Muller S ^b   Stauch, B ^b   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Anthracycline resistance; Cisplatin; Gemcitabine; HER2 overexpression; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUROSEMIDE; GEMCITABINE; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GENE OVEREXPRESSION; HUMAN; LEUKOPENIA; METASTASIS; NAUSEA AND VOMITING; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 28244469788     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.06.010     Document Type: Article

References (21)

1. D.J. Slamon B. Leyland-Jones S. Shak et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783-792
2. J. Carmichael The role of gemcitabine in the treatment of other tumours Br J Cancer 78 suppl 3 1998 21-25
3. C.J. van Moorsel H.M. Pinedo G. Veerman et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines Br J Cancer 80 1999 981-990
4. Heinemann V, Stemmler HJ, Wohlrab B, et al. Gemcitabine and cisplatin +/- trastuzumab (herceptin) in intensively pretreated metastatic breast cancer (MBC) [abstract]. Jahrestagung der DGHO 2002, Munich 27-30 October, 2002.
5. Stemmler HJ, Heinemann V, Brehm G. Response to a triple combination of gemcitabine, cisplatin and herceptin in metastatic breast cancer previously refractory to gemcitabine and herceptin: A case report [abstract]. Jahrestagung der DGHO 1999, Jena 3-6 October, 1999.
6. I. Naruse H. Fukumoto N. Saijo K. Nishio Enhanced anti-tumor effect of trastuzumab in combination with cisplatin Jpn J Cancer Res 93 2002 574-581
7. S. Chaudry H.A. Abdel-Rahman R. Patil Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (MBC) [abstract 430] Proc Am Soc Clin Oncol 19 2000 111a
8. H.F. de la Pena E. Tellez J. Bastarrachea Gemcitabine plus cisplatin as a palliative treatment in metastatic or refractory breast cancer (MRBC) [abstract] Proc Am Soc Clin Oncol 2001 1998 20
9. J.H. Doroshow M. Tetef K. Margolin Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M) pretreated metastatic breast cancer (Mbc) patients (Pts): A California Cancer Consortium/Loyola University of Chicago trial [abstract 609H] Proc Am Soc Clin Oncol 19 2000 155a
10. C.A. Galvez F. Calmarini M. Curie Monthly cisplatin (C) and gemcitabine (G) as second-line chemotherapy for patients with advanced breast cancer [abstract] Breast Cancer Res Treat 64 2000 81
11. R.A. Nagourney J.S. Link J.B. Blitzer C. Forsthoff S.S. Evans Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients J Clin Oncol 18 2000 2245-2249
12. R.A. Nagourney Gemcitabine plus cisplatin in breast cancer Oncology (Huntingt) 15 suppl 3 2001 28-33
13. C.J. van Moorsel G. Veerman A.M. Bergman et al. Combination chemotherapy studies with gemcitabine Semin Oncol 24 suppl 7 1997 S7
14. G.C. Ruiz H.F. de la Pena F.A. Meza A phase II study of gemcitabine plus cisplatin in metastatic breast cancer (MBC) [abstract] Proc Am Soc Clin Oncol 20 2001 60b
15. J.A. Ajani S.R. Welch M.N. Raber W.S. Fields I.H. Krakoff Comprehensive criteria for assessing therapy-induced toxicity Cancer Invest 8 1990 147-159
16. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1-10
17. D.R. Cox The analyses of binary data 1970 Methuen London, UK
18. E.L. Kaplan P. Meier Non-parametric estimation from incomplete observations J Am Stat Assoc 53 1959 457-481
19. J.A. O'Shaughnessy S. Vukelja T. Marsland G. Kimmel S. Ratnam J.E. Pippen Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer Clin Breast Cancer 5 2004 142-147
20. C. Christodoulou G. Fountzilas E. Razi Gemcitabine and trastuzumab combination as salvage treatment in patients with HER-2-positive metastatic breast cancer Proc Am Soc Clin Oncol 22 2003
21. U. Gatzemeier G. Groth C. Butts et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer Ann Oncol 15 2004 19-27